A Phase 4 interventional study of erlotinib [Tarceva] and vinorelbine in Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 1 site in Taiwan. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2015-07-27.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer. Patients will be randomized to receive either Tarceva (150 mg po daily) or vinorelbine (60 mg/m2 on days 1 and 8 of cycle 1 and 80 mg/m2 for the other 21 days cycles). The anticipated time on study treatment is until disease progression.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 114 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: erlotinib [Tarceva]
Drug: vinorelbine
150 mg, orally once a day for up to 6 cycles of 21 days each
60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR)
CR was defined as disappearance of all target lesions. PR was defined as at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Participants experiencing either a CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST) were classified as responders. Participants with tumour assessment unevaluable were viewed as non-responders.
Time frame: Screening, Day 1 of Cycles 3 and 5 and at End of treatment up to 1 year
Percentage of Participants Achieving Disease Control
Disease control was defined as achieving a best overall response of CR, PR, or stable disease (SD) according to RECIST criteria. Participants with tumor assessment unevaluable were viewed as uncontrolled.
Time frame: Screening, Day 1 of Cycles 3 and 5 and at End of treatment up to 1 year
Duration of Response Among Participants Who Achieved Either a CR or PR
Duration of response was defined similarly for complete and partial responders. Complete response lasted from the date the complete response was first recorded to the date on which progressive disease was first noted or date of death. Partial response lasted from the date of partial response to the date of the first observation of progressive disease or date of death.
Time frame: Screening, Day 1 of Cycles 3 and 5, every 4th cycle during post-study treatment, and every 3 cycles during follow-up
Percentage of Participants With Disease Progression
Progressive disease was defined using RECIST as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Day 1 of Cycles 1, 3, and 5 or first documentation of progressive disease or death
Time to Disease Progression
Time to disease progression was defined as the interval between the day of randomization and the first documentation of progressive disease or death.
Time frame: Day 1 of Cycles 1, 3, and 5 or first documentation of progressive disease or death
Overall Survival: Percentage of Participants With an Progressive Disease or Death
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last dose and participants with no postbaseline information were censored at the time of randomization. Progressive disease was defined per RECIST as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Day 1 of Cycles 1 through 6 to date of death or date of last follow-up assessment
Overall Survival: Time to Event
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last dose and participants with no post baseline information were censored at the time of randomization. Overall median time to event was assessed for the population that experienced an event.
Time frame: Day 1 of Cycles 1 through 6 to date of death or date of last follow-up assessment
Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT) Questionnaire
The FACT Questionnaire contains 4 general and 1 lung cancer symptom-specific subscale, including Physical Well-Being (PWB), Social/family Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and the 8-item Lung Cancer Subscale (LCS) that assess symptoms commonly reported by participants with lung cancer. Each subscale was assessed by a five-point scale from 0 (not at all) to 4 (very much) to determine the quality of life. PWB, SWB and FWB scores ranged from 0-28 and EWB scores ranged from 0-24. LCS scores ranged from 0-36. For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'. For other subscales and questionnaires, the higher score represented 'Worsened'. Missing data were replaced by the valid post-baseline assessment before. The FACT-L score ranges from 0 to 136, with higher scores indicating better quality of life.
Time frame: Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
Changes in Quality of Life as Measured by the FACT Questionnaire
The FACT Questionnaire contains 4 general and 1 lung cancer symptom-specific subscale, including PWB, SWB, EWB, FWB, and the 8-item LCS that assess symptoms commonly reported by participants with lung cancer. Each subscale was assessed by a five-point scale from 0 (not at all) to 4 (very much) to determine the quality of life. PWB, SWB and FWB scores ranged from 0-28 and EWB scores ranged from 0-24. LCS scores ranged from 0-36. For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'. For other subscales and questionnaires, the higher score represented 'Worsened'. Missing data were replaced by the valid post-baseline assessment before. For PWB, FWB, SWB, and EWB scores and disease-specific subscale score, response of down, up or no change were defined as score changes of less than or equal to (≤)2, greater than or equal to (≥)+2, or between these values.
Time frame: Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
Percentage of Participants With Changes in Quality of Life as Measured by FACT Questionnaire Scores by Category of Change
The FACT and the FACT-L contain 4 general and 1 lung cancer symptom-specific subscale, including PWB, SWB, EWB, FWB, and the 8-item LCS that assess symptoms commonly reported by participants with lung cancer. For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'. For other subscales and questionnaires, the higher score represented Worsened'. For PWB, FWB, SWB, and EWB scores and disease-specific subscale score, higher scores indicated a better outcome; a response of down, up, or no change was defined as a score change of ≤ -2 (score down), ≥ +2 (score up), or between these values.
Time frame: Baseline and End of study
Changes in Quality of Life as Assessed by FACT-L (Lung Symptoms) Questionnaire
The LCS consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition) rated on a five-point scale from 0 (not at all) to 4 (very much). The LCS total score is the sum of the scores from the 7 items. For clear thinking and good appetite, the higher score represented 'Improved'; for other subscales and questionnaires, the higher score represented 'Worsened'. Missing data were replaced by the valid post-baseline assessment before. The change of FACT-L subscore was the change from baseline to endpoint. The LCS of FACT-L is an independently validated tool that measures the disease-related symptoms of lung cancer on an overall scale of 0 (most symptomatic) to 28 (asymptomatic).
Time frame: Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
Percentage of Participants With Changes in FACT-L (Lung Symptoms) by Category of Change
The LCS consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition). The LCS total score is the sum of the scores from the 7 items, each rated on a five-point scale from 0 (not at all) to 4 (very much). For clear thinking and good appetite, the higher score represented 'Improved'; for other subscales and questionnaires, the higher score represented 'Worsened'. For each FACT-L question, the response status was defined as down, up, or no change if the score at endpoint was smaller (score down), larger than (score up), or the same as (no change) that at baseline.
Time frame: Baseline and End of study
| Milestone | Erlotinib | Vinorelbine |
|---|---|---|
| Started | 57 | 57 |
| Completed | 24 | 20 |
| Not completed | 33 | 37 |
| Withdrew: Withdrawal by subject | 3 | 5 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Lack of efficacy | 17 | 23 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 6 | 4 |
CR was defined as disappearance of all target lesions. PR was defined as at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Participants experiencing either a CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST) were classified as responders. Participants with tumour assessment unevaluable were viewed as non-responders.
| percentage of participants | Erlotinib | Vinorelbine |
|---|---|---|
| Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR) | 22.81 | 8.93 |
Disease control was defined as achieving a best overall response of CR, PR, or stable disease (SD) according to RECIST criteria. Participants with tumor assessment unevaluable were viewed as uncontrolled.
| percentage of participants | Erlotinib | Vinorelbine |
|---|---|---|
| Percentage of Participants Achieving Disease Control | 71.93 | 57.14 |
Duration of response was defined similarly for complete and partial responders. Complete response lasted from the date the complete response was first recorded to the date on which progressive disease was first noted or date of death. Partial response lasted from the date of partial response to the date of the first observation of progressive disease or date of death.
| months | Erlotinib | Vinorelbine |
|---|---|---|
| Duration of Response Among Participants Who Achieved Either a CR or PR | 10.89 (5.48 to 22.23) | 8.75 (2.75 to NA) |
Progressive disease was defined using RECIST as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| percentage of participants | Erlotinib | Vinorelbine |
|---|---|---|
| Percentage of Participants With Disease Progression | 63.16 | 58.93 |
Time to disease progression was defined as the interval between the day of randomization and the first documentation of progressive disease or death.
| months | Erlotinib | Vinorelbine |
|---|---|---|
| Time to Disease Progression | 6.66 (4.43 to 9.05) | 3.87 (2.49 to 6.92) |
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last dose and participants with no postbaseline information were censored at the time of randomization. Progressive disease was defined per RECIST as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| percentage of participants | Erlotinib | Vinorelbine |
|---|---|---|
| Overall Survival: Percentage of Participants With an Progressive Disease or Death | 56.14 | 48.21 |
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last dose and participants with no post baseline information were censored at the time of randomization. Overall median time to event was assessed for the population that experienced an event.
| months | Erlotinib | Vinorelbine |
|---|---|---|
| Overall Survival: Time to Event | 11.21 (6.79 to 19.57) | 10.36 (7.67 to NA) |
The FACT Questionnaire contains 4 general and 1 lung cancer symptom-specific subscale, including Physical Well-Being (PWB), Social/family Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and the 8-item Lung Cancer Subscale (LCS) that assess symptoms commonly reported by participants with lung cancer. Each subscale was assessed by a five-point scale from 0 (not at all) to 4 (very much) to determine the quality of life. PWB, SWB and FWB scores ranged from 0-28 and EWB scores ranged from 0-24. LCS scores ranged from 0-36. For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'. For other subscales and questionnaires, the higher score represented 'Worsened'. Missing data were replaced by the valid post-baseline assessment before. The FACT-L score ranges from 0 to 136, with higher scores indicating better quality of life.
| units on a scale | Erlotinib | Vinorelbine |
|---|---|---|
| PWB, Baseline (n=56,53) | 6.8 ± 4.0 | 6.2 ± 3.7 |
| PWB, Cycle 2 (n=52,42) | 8.1 ± 3.7 | 7.5 ± 4.4 |
| PWB, Cycle 3 (n=41,28) | 8.9 ± 4.3 | 5.7 ± 4.2 |
| PWB, Cycle 4 (n=37,28) | 9.4 ± 4.0 | 7.8 ± 6.1 |
| PWB, Cycle 5 (n=30,22) | 8.8 ± 4.3 | 7.7 ± 5.5 |
| PWB, Cycle 6 (n=25,20) | 9.3 ± 5.0 | 6.4 ± 5.5 |
| PWB, End of Study (n=52,48) | 10.8 ± 5.2 | 7.8 ± 4.5 |
| SWB, Baseline (n=55,53) | 15.9 ± 6.3 | 15.2 ± 6.8 |
| SWB, Cycle 2 (n=52,40) | 15.5 ± 6.7 | 14.7 ± 7.2 |
| SWB, Cycle 3 (n=42,30) | 16.0 ± 6.9 | 16.5 ± 6.8 |
| SWB, Cycle 4 (n=37,27) | 15.9 ± 7.0 | 16.1 ± 7.1 |
| SWB, Cycle 5 (n=28,21) | 15.7 ± 7.0 | 15.1 ± 7.7 |
| SWB, Cycle 6 (n=26,18) | 15.2 ± 7.8 | 17.4 ± 7.1 |
| SWB, End of Study (n=52,47) | 14.4 ± 7.1 | 14.3 ± 7.6 |
| EWB, Baseline (n=57,55) | 7.8 ± 3.7 | 6.5 ± 3.4 |
| EWB, Cycle 2 (n=52,43) | 6.7 ± 3.8 | 5.9 ± 3.2 |
| EWB, Cycle 3 (n=42,29) | 6.4 ± 3.5 | 5.6 ± 2.8 |
| EWB, Cycle 4 (n=37,27) | 7.0 ± 3.6 | 6.0 ± 4.6 |
| EWB, Cycle 5 (n=29,21) | 6.3 ± 3.6 | 5.5 ± 4.7 |
| EWB, Cycle 6 (n=25,20) | 6.5 ± 3.5 | 4.8 ± 3.1 |
| EWB, End of Study (n=52,50) | 7.1 ± 4.1 | 6.0 ± 3.4 |
| FWB, Baseline (n=56,55) | 12.3 ± 6.2 | 13.3 ± 7.4 |
| FWB, Cycle 2 (n=51,41) | 12.9 ± 7.1 | 12.9 ± 7.1 |
| FWB, Cycle 3 (n=41,27) | 13.0 ± 7.4 | 12.9 ± 6.9 |
| FWB, Cycle 4 (n=37,26) | 12.8 ± 7.2 | 11.3 ± 7.8 |
| FWB, Cycle 5 (n=29,22) | 12.7 ± 6.2 | 12.0 ± 7.6 |
| FWB, Cycle 6 (n=25,20) | 11.7 ± 6.4 | 11.4 ± 6.3 |
| FWB, End of Study (n=51,50) | 11.1 ± 7.2 | 11.5 ± 7.2 |
| LCS, Baseline (n=56,54) | 11.0 ± 3.2 | 11.1 ± 3.8 |
| LCS, Cycle 2 (n=50,45) | 10.8 ± 3.1 | 11.2 ± 3.5 |
| LCS, Cycle 3 (n=42,30) | 11.0 ± 3.1 | 10.5 ± 3.2 |
| LCS, Cycle 4 (n=37,27) | 11.3 ± 3.1 | 10.2 ± 3.2 |
| LCS, Cycle 5 (n=28,21) | 10.8 ± 3.0 | 10.0 ± 3.9 |
| LCS, Cycle 6 (n=26,20) | 10.4 ± 2.9 | 9.9 ± 4.0 |
| LCS, End of Study (n=52,50) | 11.1 ± 3.2 | 10.8 ± 3.2 |
The FACT Questionnaire contains 4 general and 1 lung cancer symptom-specific subscale, including PWB, SWB, EWB, FWB, and the 8-item LCS that assess symptoms commonly reported by participants with lung cancer. Each subscale was assessed by a five-point scale from 0 (not at all) to 4 (very much) to determine the quality of life. PWB, SWB and FWB scores ranged from 0-28 and EWB scores ranged from 0-24. LCS scores ranged from 0-36. For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'. For other subscales and questionnaires, the higher score represented 'Worsened'. Missing data were replaced by the valid post-baseline assessment before. For PWB, FWB, SWB, and EWB scores and disease-specific subscale score, response of down, up or no change were defined as score changes of less than or equal to (≤)2, greater than or equal to (≥)+2, or between these values.
| units on a scale | Erlotinib | Vinorelbine |
|---|---|---|
| PWB, Baseline (n=51,45) | 6.5 ± 3.8 | 6.0 ± 3.4 |
| PWB, Endpoint (n=51,45) | 10.8 ± 5.2 | 7.8 ± 4.6 |
| Change in PWB (n=51,45) | 4.3 ± 5.5 | 1.8 ± 4.7 |
| SWB, Baseline (n=50,45) | 15.8 ± 6.5 | 15.4 ± 6.7 |
| SWB, Endpoint (n=50,45) | 14.3 ± 7.2 | 14.4 ± 7.7 |
| Change in SWB (n=50,45) | -1.5 ± 4.8 | -1.0 ± 6.0 |
| EWB, Baseline (n=52,48) | 7.9 ± 3.7 | 6.2 ± 3.2 |
| EWB, Endpoint (n=52,48) | 7.1 ± 4.1 | 6.0 ± 3.4 |
| Change in EWB (n=52,48) | -0.8 ± 4.4 | -0.2 ± 4.0 |
| FWB, Baseline (n=51,48) | 12.6 ± 6.2 | 13.4 ± 7.4 |
| FWB, Endpoint (n=51,48) | 11.1 ± 7.2 | 11.7 ± 7.2 |
| Change in FWB (n=51,48) | -1.5 ± 5.1 | -1.7 ± 6.0 |
| LCS, Baseline (n=51,47) | 10.9 ± 3.3 | 11.2 ± 4.0 |
| LCS, Endpoint (n=51,47) | 11.2 ± 3.2 | 10.7 ± 3.0 |
| Change in LCS (n=51,47) | 0.3 ± 3.3 | -0.4 ± 4.5 |
The FACT and the FACT-L contain 4 general and 1 lung cancer symptom-specific subscale, including PWB, SWB, EWB, FWB, and the 8-item LCS that assess symptoms commonly reported by participants with lung cancer. For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'. For other subscales and questionnaires, the higher score represented Worsened'. For PWB, FWB, SWB, and EWB scores and disease-specific subscale score, higher scores indicated a better outcome; a response of down, up, or no change was defined as a score change of ≤ -2 (score down), ≥ +2 (score up), or between these values.
| percentage of participants | Erlotinib | Vinorelbine |
|---|---|---|
| PWB, Score Down (n=51,45) | 7.8 | 22.2 |
| PWB, No Change (n=51,45) | 33.3 | 31.1 |
| PWB, Score Up (n=51,45) | 58.8 | 46.7 |
| SWB, Score Down (n=50,45) | 40.0 | 37.8 |
| SWB, No Change (n=50,45) | 40.0 | 40.0 |
| SWB, Score Up (n=50,45) | 20.0 | 22.2 |
| EWB, Score Down (n=52,48) | 38.5 | 33.3 |
| EWB, No Change (n=52,48) | 38.5 | 41.7 |
| EWB, Score Up (n=52,48) | 23.1 | 25.0 |
| FWB, Score Down (n=51,48) | 41.2 | 41.7 |
| FWB, No Change (n=51,48) | 33.3 | 35.4 |
| FWB, Score Up (n=51,48) | 25.5 | 22.9 |
| LCS, Score Down (n=51,47) | 17.6 | 31.9 |
| LCS, No Change (n=51,47) | 47.1 | 40.4 |
| LCS, Score Up (n=51,47) | 35.3 | 27.7 |
The LCS consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition) rated on a five-point scale from 0 (not at all) to 4 (very much). The LCS total score is the sum of the scores from the 7 items. For clear thinking and good appetite, the higher score represented 'Improved'; for other subscales and questionnaires, the higher score represented 'Worsened'. Missing data were replaced by the valid post-baseline assessment before. The change of FACT-L subscore was the change from baseline to endpoint. The LCS of FACT-L is an independently validated tool that measures the disease-related symptoms of lung cancer on an overall scale of 0 (most symptomatic) to 28 (asymptomatic).
| units on a scale | Erlotinib | Vinorelbine |
|---|---|---|
| Shortness of breath, Baseline (n=52,48) | 1.4 ± 0.7 | 1.4 ± 1.1 |
| Shortness of breath, Endpoint (n=52,48) | 1.6 ± 1.0 | 1.3 ± 0.9 |
| Shortness of breath, Change (n=52,48) | 0.2 ± 0.8 | -0.1 ± 1.2 |
| Weight loss, Baseline (n=51,47) | 0.6 ± 0.8 | 0.8 ± 1.0 |
| Weight loss, Endpoint (n=51,47) | 0.7 ± 0.9 | 0.6 ± 0.7 |
| Weight loss, Change (n=51,47) | 0.1 ± 1.0 | -0.2 ± 1.2 |
| Clear thinking, Baseline (n=52,48) | 2.4 ± 1.2 | 2.3 ± 1.3 |
| Clear thinking, Endpoint (n=52,48) | 2.2 ± 1.3 | 2.4 ± 1.3 |
| Clear thinking, Change (n=52,48) | -0.2 ± 1.1 | 0.1 ± 1.5 |
| Coughing, Baseline (n=52,48) | 1.3 ± 0.6 | 1.4 ± 1.0 |
| Coughing, Endpoint (n=52,48) | 1.4 ± 0.7 | 1.4 ± 0.8 |
| Coughing, Change (n=52,48) | 0.1 ± 0.8 | -0.0 ± 1.2 |
| Hair loss, Baseline (n=52,48) | 0.3 ± 0.6 | 0.6 ± 1.1 |
| Hair loss, Endpoint (n=52,48) | 0.4 ± 0.7 | 0.4 ± 0.6 |
| Hair loss, Change (n=52,48) | 0.1 ± 0.8 | -0.1 ± 1.2 |
| Good appetite, Baseline (n=52,48) | 1.9 ± 0.9 | 2.0 ± 1.2 |
| Good appetite, Endpoint (n=52,48) | 1.7 ± 1.1 | 1.7 ± 1.0 |
| Good appetite, Change (n=52,48) | -0.3 ± 0.9 | -0.4 ± 1.3 |
| Tightness in chest, Baseline (n=52,48) | 1.3 ± 0.8 | 1.2 ± 0.9 |
| Tightness in chest, Endpoint (n=52,48) | 1.4 ± 0.8 | 1.3 ± 1.0 |
| Tightness in chest, Change (n=52,48) | 0.1 ± 0.9 | 0.1 ± 1.2 |
| Easy breathing, Baseline (n=52,48) | 1.7 ± 0.9 | 1.7 ± 1.1 |
| Easy breathing, Endpoint (n=52,48) | 1.7 ± 0.9 | 1.6 ± 1.1 |
| Easy breathing, Change (n=52,48) | -0.1 ± 1.1 | -0.0 ± 1.3 |
The LCS consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition). The LCS total score is the sum of the scores from the 7 items, each rated on a five-point scale from 0 (not at all) to 4 (very much). For clear thinking and good appetite, the higher score represented 'Improved'; for other subscales and questionnaires, the higher score represented 'Worsened'. For each FACT-L question, the response status was defined as down, up, or no change if the score at endpoint was smaller (score down), larger than (score up), or the same as (no change) that at baseline.
| percentage of participants | Erlotinib | Vinorelbine |
|---|---|---|
| Shortness of breath, Score Down (n=52,48) | 17.3 | 18.8 |
| Shortness of breath, No Change (n=52,48) | 51.9 | 58.3 |
| Shortness of breath, Score Up (n=52,48) | 30.8 | 22.9 |
| Weight loss, Score Down (n=51,47) | 19.6 | 31.9 |
| Weight loss, No Change (n=51,47) | 51.0 | 44.7 |
| Weight loss, Score Up (n=51,47) | 29.4 | 23.4 |
| Clear thinking, Score Down (n=52,48) | 26.9 | 27.1 |
| Clear thinking No Change (n=52,48) | 53.8 | 43.8 |
| Clear thinking, Score Up (n=52,48) | 19.2 | 29.2 |
| Coughing, Score Down (n=52,48) | 21.2 | 22.9 |
| Coughing, No Change (n=52,48) | 53.8 | 50.0 |
| Coughing, Score Up (n=52,48) | 25.0 | 27.1 |
| Hair loss, Score Down (n=52,48) | 13.5 | 18.8 |
| Hair loss, No Change (n=52,48) | 65.4 | 60.4 |
| Hair loss, Score Up (n=52,48) | 21.2 | 20.8 |
| Good appetite, Score Down (n=52,48) | 26.9 | 35.4 |
| Good appetite, No Change (n=52,48) | 61.5 | 45.8 |
| Good appetite, Score Up (n=52,48) | 11.5 | 18.8 |
| Tightness in chest, Score Down (n=52,48) | 17.3 | 22.9 |
| Tightness in chest, No Change (n=52,48) | 55.8 | 54.2 |
| Tightness in chest, Score Up (n=52,48) | 26.9 | 22.9 |
| Easy breathing, Score Down (n=52,48) | 28.8 | 22.9 |
| Easy breathing, No Change (n=52,48) | 48.1 | 58.3 |
| Easy breathing, Score Up (n=52,48) | 23.1 | 18.8 |
Collected over Adverse Events were monitored continuously during the study treatment and for 28 days after the last intake of study medication. Only SAE were recorded during post study treatment phase and for 28 days after the last intake of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Erlotinib | — | 19/57 (33.3%) | 54/55 (98.2%) |
| Vinorelbine | — | 14/57 (24.6%) | 53/54 (98.1%) |
| Event | Erlotinib | Vinorelbine |
|---|---|---|
| PneumoniaInfections and infestations | 4/57 | 6/57 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/57 | 3/57 |
| NeutropeniaBlood and lymphatic system disorders | 0/57 | 1/57 |
| Cardiogenic shockCardiac disorders | 1/57 | 0/57 |
| Cardiopulmonary failureCardiac disorders | 1/57 | 0/57 |
| Cardiac arrestCardiac disorders | 0/57 | 1/57 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/57 | 0/57 |
| MelaenaGastrointestinal disorders | 0/57 | 1/57 |
| VomitingGastrointestinal disorders | 0/57 | 1/57 |
| AstheniaGeneral disorders | 1/57 | 0/57 |
| Event | Erlotinib | Vinorelbine |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 38/55 | 3/54 |
| Decreased appetiteMetabolism and nutrition disorders | 16/55 | 24/54 |
| DiarrhoeaGastrointestinal disorders | 20/55 | 7/54 |
| Mouth ulcerationGastrointestinal disorders | 9/55 | 1/54 |
| PyrexiaGeneral disorders | 3/55 | 8/54 |
| ConstipationGastrointestinal disorders | 7/55 | 7/54 |
| InsomniaPsychiatric disorders | 5/55 | 7/54 |
| VomitingGastrointestinal disorders | 4/55 | 6/54 |
| FatigueGeneral disorders | 1/55 | 6/54 |
| NauseaGastrointestinal disorders | 3/55 | 5/54 |
Intent-to-treat (ITT) population: all randomized participants who received at least one dose of study medication.
| Age, Continuous(years) | Erlotinib | Vinorelbine | Total |
|---|---|---|---|
| Mean | 78 ± 4.98 | 78 ± 5.32 | 78 ± 5.60 |
| Sex: Female, Male(Participants) | Erlotinib | Vinorelbine | Total |
|---|---|---|---|
| Female | 10 | 11 | 21 |
| Male | 47 | 45 | 92 |
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.